Meros Investment Management LP Sells 253,528 Shares of Embecta Corp. $EMBC

Meros Investment Management LP lessened its stake in shares of Embecta Corp. (NASDAQ:EMBC) by 52.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 231,244 shares of the company’s stock after selling 253,528 shares during the quarter. Meros Investment Management LP owned about 0.39% of Embecta worth $2,747,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Larson Financial Group LLC boosted its position in shares of Embecta by 368.6% during the 3rd quarter. Larson Financial Group LLC now owns 2,001 shares of the company’s stock worth $28,000 after purchasing an additional 1,574 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in Embecta by 542.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 7,371 shares of the company’s stock valued at $71,000 after acquiring an additional 6,224 shares in the last quarter. Wexford Capital LP bought a new position in Embecta in the 3rd quarter valued at about $94,000. Humankind Investments LLC bought a new position in Embecta in the 2nd quarter valued at about $111,000. Finally, iSAM Funds UK Ltd bought a new position in Embecta in the 3rd quarter valued at about $115,000. Institutional investors own 93.83% of the company’s stock.

Analyst Ratings Changes

EMBC has been the topic of several recent research reports. Zacks Research cut shares of Embecta from a “hold” rating to a “strong sell” rating in a research report on Friday, May 8th. Mizuho dropped their price target on shares of Embecta from $12.00 to $5.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 6th. Weiss Ratings cut shares of Embecta from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Wednesday, May 6th. Bank of America dropped their price target on shares of Embecta from $11.00 to $3.00 and set an “underperform” rating on the stock in a research report on Monday, May 18th. Finally, Wall Street Zen cut shares of Embecta from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 9th. Two investment analysts have rated the stock with a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Strong Sell” and an average target price of $11.00.

Embecta Stock Up 1.0%

Embecta stock opened at $3.13 on Tuesday. Embecta Corp. has a 52 week low of $2.77 and a 52 week high of $15.55. The company’s 50 day moving average price is $5.65 and its two-hundred day moving average price is $9.02. The stock has a market cap of $185.70 million, a P/E ratio of 1.65 and a beta of 0.84.

Embecta (NASDAQ:EMBC) last posted its earnings results on Tuesday, May 5th. The company reported $0.27 EPS for the quarter, missing the consensus estimate of $0.42 by ($0.15). Embecta had a negative return on equity of 23.96% and a net margin of 10.73%.The firm had revenue of $221.80 million for the quarter, compared to the consensus estimate of $235.67 million. During the same period in the prior year, the business earned $0.70 EPS. Embecta’s quarterly revenue was down 14.4% compared to the same quarter last year. Embecta has set its FY 2026 guidance at 1.550-1.75 EPS. On average, equities analysts anticipate that Embecta Corp. will post 1.62 EPS for the current year.

Embecta Cuts Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, June 15th. Stockholders of record on Thursday, May 28th were paid a dividend of $0.01 per share. This represents a $0.04 dividend on an annualized basis and a dividend yield of 1.3%. The ex-dividend date was Thursday, May 28th. Embecta’s payout ratio is presently 2.11%.

Embecta Company Profile

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.